Source Count: 12 | Weighted Score: 27 | Source Confidence: [3/5] | Primary Tier: 1 | Last Updated: March 11, 2026
Keywords: longevity, aging, senescence, senolytic, telomere, telomerase, caloric restriction, rapamycin, mTOR, NAD+, sirtuin, epigenetic clock, Horvath clock, lifespan, healthspan, geroscience, metformin, parabiosis, Yamanaka factor, rejuvenation
Category Tags: future-technology, longevity, aging, senolytic, telomere, geroscience, lifespan-extension
Cross-References: Z_2_02 — Telomere Biology · Z_2_02 — Aging Biology · X_1_01 — Medicine Overview

QUICK SUMMARY

Longevity science — the systematic study of biological aging with the goal of extending human healthspan (years of healthy life) and potentially lifespan — has transformed from a fringe pursuit into a mainstream biomedical discipline fueled by discoveries in the molecular mechanisms of aging. The Hallmarks of Aging framework (López-Otín et al., 2013; updated 2023) identifies 12 interconnected processes driving age-related decline: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation ("inflammaging"), and dysbiosis. Among the most promising intervention targets: senolytics — drugs that selectively eliminate senescent ("zombie") cells that accumulate with age and secrete inflammatory factors (the SASP — senescence-associated secretory phenotype). Dasatinib + quercetin and fisetin have shown senolytic effects in animal models and early human trials. Caloric restriction (CR) extends lifespan by 20–40% in organisms from yeast to primates, operating through the mTOR and insulin/IGF-1 pathways — leading to investigation of CR mimetics like rapamycin and metformin (the TAME trial). Telomere biology (Blackburn, Greider, Szostak — 2009 Nobel) revealed telomerase as a critical factor in cellular aging. Epigenetic clocks (Horvath, 2013) can measure biological age from DNA methylation patterns with remarkable accuracy, providing a biomarker for aging interventions. Most recently, partial cellular reprogramming using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc) has shown the ability to reverse epigenetic age in animal tissues without causing dedifferentiation — opening the door to potential rejuvenation therapies.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 Hallmarks of Aging

• López-Otín et al. (2013, updated 2023) identified 12 hallmarks:

1. Genomic instability: accumulation of DNA damage from endogenous and exogenous sources
2. Telomere attrition: progressive shortening of chromosome-protective telomere caps
3. Epigenetic alterations: changes in DNA methylation, histone modifications, and chromatin remodeling
4. Loss of proteostasis: decline in protein folding quality control (chaperones, proteasome, autophagy)
5. Disabled macroautophagy: reduced clearance of damaged organelles and proteins
6. Deregulated nutrient sensing: dysfunction in insulin/IGF-1, mTOR, AMPK, and sirtuin pathways
7. Mitochondrial dysfunction: reduced oxidative phosphorylation, increased ROS, mitochondrial DNA mutations
8. Cellular senescence: accumulation of growth-arrested cells secreting pro-inflammatory SASP factors
9. Stem cell exhaustion: declining regenerative capacity
10. Altered intercellular communication: changes in endocrine, neuroendocrine, and immune signaling
11. Chronic inflammation ("inflammaging")
12. Dysbiosis: age-related microbiome alterations

1.2 Caloric Restriction and Nutrient Sensing Pathways

• Caloric restriction (CR): reducing caloric intake by 20–40% without malnutrition extends lifespan in yeast, worms, flies, and rodents consistently; in rhesus monkeys (Wisconsin/NIA studies), CR reduces age-related disease and mortality
• Key pathways: mTOR (mechanistic target of rapamycin): a nutrient-sensing kinase; inhibition by rapamycin extends mouse lifespan by 10–15% even when started in late life (Harrison et al., 2009)
• Metformin: a widely used diabetes drug that activates AMPK and suppresses mTOR; associated with reduced all-cause mortality in diabetic patients vs. non-diabetic controls — prompting the TAME (Targeting Aging with Metformin) trial

1.3 Telomeres and Telomerase

• Telomeres: repetitive DNA sequences (TTAGGG in humans) capping chromosome ends, shortening with each cell division (the end-replication problem)
• Telomerase: a reverse transcriptase enzyme that extends telomeres — highly active in stem cells and cancer cells, largely inactive in most somatic cells
• Blackburn, Greider & Szostak: 2009 Nobel Prize for discovering telomerase and its role in chromosome maintenance
• Short telomere syndromes (dyskeratosis congenita, aplastic anemia) demonstrate that critically short telomeres cause premature aging phenotypes

1.4 Epigenetic Clocks

• Horvath clock (2013): predicts chronological age (±3.6 years) from DNA methylation at 353 CpG sites — remarkably accurate across tissues, cell types, and species
• Biological age can diverge from chronological age: accelerated epigenetic aging predicts earlier mortality, cardiovascular disease, and cancer
• Epigenetic clocks serve as biomarkers for evaluating anti-aging interventions — reduced biological age indicates potential rejuvenation

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Senolytics

• Senescent cells accumulate with age, secreting SASP (IL-6, IL-8, MMPs, TGF-β) that damages surrounding tissue and drives chronic inflammation:
• Dasatinib + quercetin (D+Q): first generation senolytics; reduced senescent cell burden and improved physical function in aged mice and in a pilot human trial (idiopathic pulmonary fibrosis patients — Justice et al., 2019)
• Fisetin: plant flavonoid with senolytic activity; improved healthspan in aged mice
• Navitoclax (ABT-263): targets BCL-2 family anti-apoptotic proteins; potent senolytic but causes thrombocytopenia
• Multiple clinical trials are now underway for senolytics in various age-related diseases; efficacy and safety in humans remain to be established at scale

2.2 Partial Cellular Reprogramming

• Yamanaka factors (Oct4, Sox2, Klf4, c-Myc — OSKM): when expressed briefly (cyclic reprogramming), can reverse epigenetic age markers in mouse tissues without resetting cellular identity or causing teratomas (Ocampo et al., 2016; Lu et al., 2020):
• In vivo cyclic OSKM in progeria mice extended lifespan and improved tissue function
• Altos Labs (founded 2022) and other ventures are pursuing reprogramming-based rejuvenation in human applications
• Whether this can be safely translated to humans is unknown — cancer risk from c-Myc is a major concern

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Radical Life Extension

• Anti-aging advocates (e.g., Aubrey de Grey's SENS framework) propose that comprehensive damage repair could achieve "longevity escape velocity" — extending life faster than aging progresses, theoretically leading to indefinite lifespans. While philosophically provocative, no current intervention approaches this threshold, and the social, economic, and ethical implications of radical life extension remain largely unexplored

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Anti-Aging Supplements Reliably Extend Human Lifespan

• [UNSUBSTANTIATED] Despite marketing claims, no over-the-counter supplement (NMN, NR, resveratrol, CoQ10) has been demonstrated in randomized controlled trials to extend human lifespan. Some show promise in animal models or biomarker improvements in humans, but definitive evidence for lifespan extension in humans is lacking

COUNTER-ARGUMENTS

• SENS approach criticized: S. Jay Olshansky (University of Illinois at Chicago, 2002, Scientific American) and Leonard Hayflick have criticized Aubrey de Grey’s SENS (Strategies for Engineered Negligible Senescence) framework as oversimplifying the biology of aging, arguing that aging is not a disease with discrete fixable causes but an entropic process deeply embedded in cellular thermodynamics — 28 biogerontologists co-signed a 2005 EMBO Reports paper questioning whether SENS targets were scientifically actionable
• Telomere extension risks: while telomerase activation can extend telomeres, Maria Blasco (CNIO, Madrid) and others have demonstrated that constitutive telomerase expression in mammals increases cancer risk because it removes a key tumor-suppressive checkpoint — the relationship between telomere maintenance and oncogenesis remains a fundamental obstacle to telomere-based anti-aging interventions

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. López-Otín, Carlos, et al | 2023 | "Hallmarks of Aging: An Expanding Universe" | Cell | ∅ | 186.2::243–278 | ∅ | ∅ | doi:10.1016/j.cell.2022.11.001 | ∅ | ∅ | ∅
2. López-Otín, Carlos, et al | 2013 | "The Hallmarks of Aging" | Cell | ∅ | 153.6::1194–1217 | ∅ | ∅ | doi:10.1016/j.cell.2013.05.039 | ∅ | ∅ | ∅
3. Harrison, David E., et al | 2009 | "Rapamycin Fed Late in Life Extends Lifespan in Genetically Heterogeneous Mice" | Nature | ∅ | 460::392–395 | ∅ | ∅ | doi:10.1038/nature08221 | ∅ | ∅ | ∅
4. Horvath, Steve | 2013 | "DNA Methylation Age of Human Tissues and Cell Types" | ( Paper remains valid and widely cited.) | Genome Biology | 14::R115 | ∅ | ∅ | correction-doi:10.1186/s13059-015-0649-6, doi:10.1186/gb-2013-14-10-r115 | ∅ | ∅ | ∅
5. Xu, Ming, et al | 2018 | "Senolytics Improve Physical Function and Increase Lifespan in Old Age" | Nature Medicine | ∅ | 24::1246–1256 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
6. Ocampo, Alejandro, et al | 2016 | "In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming" | Cell | ∅ | 167.7::1719–1733 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
7. Blackburn, Elizabeth H., Elissa S | 2015 | "Human Telomere Biology: A Contributory and Interactive Factor in Aging, Disease Risks, and Protection" | Science | ∅ | 350.6265::1193–1198 | Epel, and Jue Lin | ∅ | ∅ | ∅ | ∅ | ∅
8. Campisi, Judith | 2013 | "Aging, Cellular Senescence, and Cancer" | Annual Review of Physiology | ∅ | 75::685–705 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
9. Fontana, Luigi, Linda Partridge; Valter D | 2010 | "Extending Healthy Life Span — From Yeast to Humans" | Science | ∅ | 328.5976::321–326 | Longo | ∅ | ∅ | ∅ | ∅ | ∅
10. Justice, Jamie N., et al | 2019 | "Senolytics in Idiopathic Pulmonary Fibrosis: Results from a First-in-Human, Open-Label, Pilot Study" | EBioMedicine | ∅ | 40::554–563 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
11. Lu, Yuancheng, et al | 2020 | "Reprogramming to Recover Youthful Epigenetic Information and Restore Vision" | Nature | ∅ | 588::124–129 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
12. de Grey, Aubrey D.N.J.; Michael Rae | 2007 | ∅ | Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime | ∅ | ∅ | New York: St | ∅ | ∅ | ∅ | ∅ | Martin's Press

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: March 11, 2026